Skip to main content

Table 2 Effect of octreotide on left ventricular hemodynamic parameters in hyperthyroid rat hearts exposed to ischemia/reperfusion

From: Octreotide (somatostatin analog) attenuates cardiac ischemia/reperfusion injury via activating nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway in rat model of hyperthyroidism

 

Baseline

Reperfusion (min) time-point

30

60

120

LVEDP (mmHg)

    

Control

8.5 ± 1.01

33.8 ± 2.3

31.2 ± 3.2

29.2 ± 2.7

HTC

9.3 ± 1.4

43.5 ± 3.6*

41.7 ± 2.9*

38.9 ± 3*

HT+OCT

8.7 ± 1.5

35.3 ± 1.7#

32 ± 3.7#

30.8 ± 3.1#

HT+BRU+OCT

9.5 ± 1.98

41.4 ± 2.5*$

40.1 ± 2.7*$

37.7 ± 4.9*$

LVDP (% of baseline)

  

Control

100 (93.2 ± 8.4 mmHg)

62.1 ± 2.8

50.9 ± 3.4

37.2 ± 3.2

HTC

100 (72.2 ± 8.8 mmHg)*

54.2 ± 3.5*

43.7 ± 3.1*

29.5 ± 3.3*

HT+OCT

100 (84.2 ± 6.01 mmHg)*#

63.1 ± 2.8#

52.3 ± 3.5#

35.6 ± 4.1#

HT+BRU+OCT

100 (75.4 ± 8.3 mmHg)*$

53.1 ± 3.3*$

42.1 ± 4.1*$

28.2 ± 3.8*$

Max. dP/dt (% of baseline)

    

Control

100 (2794 ± 121 mmHg/s)

60.3 ± 3.8

49.1 ± 4.8

36.6 ± 3.6

HTC

100 (2457 ± 102 mmHg/s)*

53.8 ± 4.1*

42.1 ± 4.4*

28.5 ± 3.6*

HT+OCT

100 (2672 ± 160 mmHg/s)*#

62.1 ± 2.6#

51.1 ± 2.3#

37.8 ± 4.9#

HT+BRU+OCT

100 (2531 ± 106 mmHg/s)*$

52.1 ± 3.2*$

41.4 ± 3.2*$

29.6 ± 2.9*$

Min. dP/dt (% of baseline)

    

Control

100 (2025 ± 199 mmHg/s)

59.6 ± 3.5

47.9 ± 4.4

38.2 ± 4.7

HTC

100 (1401 ± 117 mmHg/s)*

52.4 ± 3.9*

39.7 ± 3.9*

28.5 ± 3.6*

HT+OCT

100 (1788 ± 124 mmHg/s)*#

60.1 ± 3.1#

48.1 ± 4.9#

36.8 ± 4.6#

HT+BRU+OCT

100 (1336 ± 116 mmHg/s)*$

50.9 ± 4.4*$

38.4 ± 2.9*$

27.9 ± 3.7*$

  1. n = 10 in each group. Data are represented as mean ± SD
  2. LVEDP left ventricular end diastolic pressure, LVDP left ventricular developed pressure, max. dP/dt LV maximal derivative of pressure, min. dP/dt LV minimal derivative of pressure
  3. Significance (P < 0.05): *significant when compared with the control group, #significant when compared with HTC groups, $significant when compared with HT+OCT